Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties-Reference-Cited by-同舟云学术

Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties

Published:2022-07-05 Issue:7 Volume:13 Page:1165-1171
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Hill Matthew D.¹,Fang Haiquan²,Norris Derek³,Delucca George V.³,Huang Hong²,DeBenedetto Mikkel²,Quesnelle Claude³,Schmitz William D.³,Tokarski John S.³,Sheriff Steven³,Yan Chunhong³,Fanslau Caroline³,Haarhoff Zuzana³,Huang Christine³,Kramer Melissa²,Madari Shilpa³,Menard Krista³,Monereau Laura³,Morrison John³,Raghavan Nirmala³,Shields Eric E.²,Simmermacher-Mayer Jean²,Sinz Michael³,Tye Ching Kim³,Westhouse Richard³,Xie Chunshan³,Zhang Haiying³,Zhang Lisa³,Zvyaga Tatyana³,Lee Francis³,Gavai Ashvinikumar V.³,Degnan Andrew P.³^ORCID

Affiliation:

1. Research & Development, Bristol Myers Squibb Company, 100 Binney Street, Cambridge, Massachusetts 02142, United States

2. Research & Development, Bristol Myers Squibb Company, Wallingford, Connecticut 06492, United States

3. Research & Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00219

Reference20 articles.

1. Strategies to Inhibit Myc and Their Clinical Applicability